Streamlining Generic Drug Immunogenicity Evaluation: EpiVax's "PANDA" Approach
- Written by PR Newswire
![]() |
PROVIDENCE, R.I., Aug. 11, 2023 /PRNewswire/ -- EpiVax Inc. announces the publication of results from a research collaboration with the Food and Drug Administration aimed at streamlining generic drug evaluations. The research, initiated in 2018 with a $1M contract spanning two years (HHSF223018186C), was established to develop best practices for...
Read more: Streamlining Generic Drug Immunogenicity Evaluation: EpiVax's "PANDA" Approach